Sunday, February 06, 2011 5:18:19 AM
"We have already seen a similar device that is on the market in the EU have data published in JAMA"
First, we have addressed this before that Toraymyxin's ability to filter entoxins is limited in time due to the fact that only early treatment is usful in this regard. Removal of endotoxins doesn't actively treat the cytokine storm but trying to address the pathogen itself while the organ failure and tissue damage is caused by the immune system itself against the body, not directly from the pathogen.
Second, Endotoxins is limited to bacteria pathogens. Mostly gram-negatives. This limits the treatment especially for viruses that cause the major contributor for sepsis (e.g Pandemic flu, H1N1(swine flu) and so on).
"Most big pharma have exited the device business"
prove this.
"Could the CTSO device be beter? Yes, but that has to be proven and the current study does not even address that question."
what you're saying is very misleading, if the study demonstrates huge difference between control group and treatment group, no one can doubt it. for that there's a p-value too. Generally the medical community seeks treatments that work. if CTSO shows favorable results and the device proved to be effective, market penetration can be easily achieved.
First, we have addressed this before that Toraymyxin's ability to filter entoxins is limited in time due to the fact that only early treatment is usful in this regard. Removal of endotoxins doesn't actively treat the cytokine storm but trying to address the pathogen itself while the organ failure and tissue damage is caused by the immune system itself against the body, not directly from the pathogen.
Second, Endotoxins is limited to bacteria pathogens. Mostly gram-negatives. This limits the treatment especially for viruses that cause the major contributor for sepsis (e.g Pandemic flu, H1N1(swine flu) and so on).
"Most big pharma have exited the device business"
prove this.
"Could the CTSO device be beter? Yes, but that has to be proven and the current study does not even address that question."
what you're saying is very misleading, if the study demonstrates huge difference between control group and treatment group, no one can doubt it. for that there's a p-value too. Generally the medical community seeks treatments that work. if CTSO shows favorable results and the device proved to be effective, market penetration can be easily achieved.
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 11:00:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 11:04:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:27:51 PM
- CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/25/2026 08:05:00 PM
- CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 • PR Newswire (US) • 03/19/2026 01:44:00 PM
- CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/05/2026 12:00:00 PM
- CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update • PR Newswire (US) • 01/12/2026 12:00:00 PM
- CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 • PR Newswire (US) • 12/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 02:09:45 AM
- Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London • PR Newswire (US) • 11/17/2025 10:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:34:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:32:19 PM
- CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update • PR Newswire (US) • 11/13/2025 09:05:00 PM
- CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London • PR Newswire (US) • 11/11/2025 12:00:00 PM
- CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 10/30/2025 11:00:00 AM
- In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer • PR Newswire (US) • 10/28/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2025 08:20:54 PM
- CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen • PR Newswire (US) • 09/29/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2025 08:35:38 PM
- CytoSorbents Provides DrugSorb-ATR Regulatory Update • PR Newswire (US) • 09/16/2025 11:00:00 AM
- CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day • PR Newswire (US) • 09/08/2025 11:00:00 AM
- CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference • PR Newswire (US) • 09/05/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2025 08:05:59 PM
- CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR • PR Newswire (US) • 08/20/2025 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2025 07:47:54 PM
